AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
SAN FRANCISCO -- Hydroxychloroquine to treat rheumatic disease seemed safe in a retrospective study of 60 pregnancies, but a separate study found that the drug does cross the placental barrier to the fetus.
The antimalarial medication is widely used to treat rheumatic disease, but controversy remains about whether to stop treatment during pregnancy. One case of fetal ototoxicity has been associated with use of the drug during pregnancy.
Because of its long half-life, discontinuing hydroxychloroquine in pregnancy will not necessarily prevent fetal exposure and may actually precipitate a flare of disease, particularly in patients with systemic lupus erythematosus, Dr. Angela Tincani said during the annual meeting of the American College of Rheumatology.
She reported on 60 pregnancies since 1995 in 55 women taking hydroxychioroquine for rheumatid disease, mainly systemic lupus (36 patients). All had been taking the drug for at least 1 year before becoming pregnant and were continued on 200 mg/day throughout gestation and after delivery Patients also took 100 mg/day of aspirin and, when needed, sometimes used other drugs such as corticosteroids, heparin, or azathioprine.
Fifty newborns (83%) were delivered at term; six (10%) were preterm deliveries. One fetus (2%) died and three (5%) were aborted. The babies weighed a mean of 3,000 g at birth; one had intrauterine growth retardation, and seven were small for gestational age. No malformations were detected. Two urinary tract infections and one streptococcal pneumonia detected at birth resolved with treatment.
Ophthalmologic exams in 16 of the infants 1 month and 12 months after birth found no abnormalities. Two babies developed retinal hemorrhages immediately after delivery-a ...
Source: HighBeam Research, Crosses the placental barrier: Study shows hydroxychloroquine safe in...